Recommendations For Identifying and Achieving Early Treatment Targets

Target Audience

The educational design of this activity addresses the needs of rheumatologists and other clinicians involved in the management of patients with moderate to severe systemic lupus erythematosus (SLE).

Program Overview

In this educational program, Drs. Eric Morand and Marta Mosca will be discussing the clinical implications of the updated European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of SLE and LN with specific detailed information and expert opinions on best practices for developing steroid-sparing regimens to achieve clinical remission or at least maintain low disease activity in patients with SLE and lupus nephritis (LN).

Educational Objectives

After completing this activity, the participant should be better able to:

• Individualize steroid-sparing treatment regimens for patients with moderate to severe SLE based on clinical manifestations and an ongoing evaluation of treatment goals

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Professor Eric Morand, MBBS (Hons), PhD, FRACP: Consulting Fees: AbbVie Inc., AstraZeneca, Biogen Inc., Bristol Myers Squibb Company, Dragonfly Therapeutics, EMD Serono, Inc., Galapagos NV, Genentech, Inc., GSK plc, IGM Biosciences, Inc, Nexstone Innovations LLC, Novartis Pharmaceuticals Corporation, RemeGen Pharmaceuticals, Inc., Takeda; Contracted Research: AbbVie Inc., Amgen Inc., AstraZeneca, Biogen Inc., Bristol Myers Squibb Company, Eli Lilly, EMD Serono, Inc., Genentech, Inc., GSK plc, Janssen Pharmaceutical Companies, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company Limited, UCB S.A.

Marta Mosca, MD, PhD: Consulting Fees: AstraZeneca, GSK plc, UCB S.A.; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AbbVie Inc., AstraZeneca, GSK plc, Otsuka Pharmaceutical Co., Ltd

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.